By Fineline Cube 
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) announced today that its self‑developed Class III injectable cross‑linked sodium hyaluronate gel has been approved by the National Medical Products Administration (NMPA). The device is cleared for injection into the mid‑to‑deep dermis of the nasolabial folds to correct moderate‑to‑severe wrinkles.
Technology Behind the Product
The gel employs chemical cross‑linking to create a three‑dimensional network of hyaluronic acid molecules. This structure delivers high cohesion and controllable biodegradability, providing immediate volumizing effects through physical support while simultaneously stimulating the body’s own collagen regeneration.
Clinical Application and Benefits
Administered via a minimally invasive injection, the filler can be precisely placed in the mid‑to‑deep dermis, making it ideal for correcting nasolabial folds and improving facial wrinkles. Its dual action—instant correction coupled with long‑term collagen induction—positions it as a promising option for patients seeking durable aesthetic outcomes.
Regulatory Significance
The NMPA approval marks a milestone for Lepu Medical, underscoring the company’s commitment to advancing safe and effective medical devices. With the clearance in hand, Lepu will pursue broader commercialization and potential export opportunities, expanding its footprint in the competitive aesthetic medicine market.-Fineline Info & Tech